US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by LEADS BIOLABS CO., LTD.
Leads Biolabs Presents Opamtistomig (PD-L1/4-1BB Bispecific Antibody) to Global Investors at the 2026 Jefferies Global Healthcare Conference
November 20, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs Doses First Patient with Systemic Lupus Erythematosus in Phase I Part B Trial of LBL-047, a First-in-Class BDCA2/TACI Bifunctional Fusion Protein
October 30, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
October 25, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study
October 20, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress
October 19, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer
October 16, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
October 11, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
September 28, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations
September 21, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
September 14, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
August 24, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
August 20, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies
April 21, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
April 09, 2026
From
LEADS BIOLABS CO., LTD.
Via
GlobeNewswire